Evidence map›Paper›PMID 29169961›Full record

ArticleNeuropharmacology2018

The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release.

Alexandre Seillier, Andrea Giuffrida

Abstract read
In one paragraph

Article in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Endocannabinoids in Body Weight Control.Pharmaceuticals (Basel, Switzerland) · 2018
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alexandre SeillierDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. Electronic address: alex.seillier@free.fr.
Andrea GiuffridaDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA. Electronic address: giuffrida@uthscsa.edu.
The University of Texas Health Science Center at San Antonio · US

Funding

Endocannabinoid transmission in schizophreniaR01MH091130 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI GIUFFRIDA, ANDREA · 2011 to 2015
$1.9M
NIMH NIH HHS R01 MH091130
6 · The paper itself

Abstract

Experimental evidence suggests that the transport of endocannabinoids might work bi-directionally. Accordingly, it is possible that pharmacological blockade of the latter affects not only the re-uptake, but also the release of endocannabinoids, thus preventing them from stimulating CB

Indexed as

Social BehaviorAmidohydrolasesAmygdalaAnimalsArachidonic AcidsBehavior, AnimalBenzamidesBenzodioxolesBenzyl CompoundsCannabinoid Receptor ModulatorsCarbamatesEndocannabinoidsFatty Acid Amide HydrolasesMalePiperidinesRatsAmidohydrolasesArachidonic AcidsBenzamidesBenzodioxolesBenzyl CompoundsCannabinoid Receptor ModulatorsCarbamatescyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl esterEndocannabinoidsFatty Acid Amide HydrolasesJZL 184OMDM-2 cpdPiperidinesReceptor, Cannabinoid, CB12-AGAmygdalaCannabinoidCholecystokininPhencyclidineSocial interaction

Identifiers

PMID29169961
PMCPMC13654241
OpenAlexW2768689591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.